Microeconomic surplus in health care: Applied economic theory in health care in four European countries

Frontiers in Pharmacology

Volumn 4 FEB, Issue , 2013, Pages

  Walzer, S ^a   Nuijten, M ^b   Wiesner, C ^c   Kaier, K ^d   Johansson, P O ^e   Oertel, S ^c  

^a MArS Market Access and Pricing Strategy GmbH   (Germany)

^b Ars Accessus Medica   (Netherlands)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF FREIBURG   (Germany)

^e STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Convenience; Health care; Health care policy; Microeconomic surplus

Indexed keywords

APPLIED ECONOMIC THEORY; ARTICLE; CESAREAN SECTION; DIAGNOSTIC TEST; DRUG RESPONSE; DRUG USE; ECONOMIC ASPECT; EMERGENCY CARE; FERTILIZATION IN VITRO; GERMANY; HEALTH CARE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; LIVE BIRTH; MICROECONOMIC SURPLUS; NETHERLANDS; PREGNANCY; SPAIN; THEORY; UNITED KINGDOM;

EID: 84881519897     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00017     Document Type: Article

References (18)

1. Assisted Reproductive Technology. (2009). Success Rates. National Summary and Fertility Clinic Reports. National Center for Chronic Disease Prevention and Health Promotion. Division of Reproductive Health. Available at: http://www.cdc.gov/art/ART2009/PDF/ART_2009_Full.pdf [accessed September 4, 2012].
2. Cabral, L. M. B. (2002). Introduction to Industrial Organization. Cambridge: MIT Press.
3. Carey, K. D., Garton, A. J., Romero, M. S., Kahler, J., Thomson, S., Ross, S., et al. (2006). Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66, 8163-8171.
4. Consejo General de Colegios Oficiales de Farmacéuticos. (2012). September 2012. Available at: http://www.portalfarma.com/Paginas/default.aspx
5. D'Addario, G., Früh, M., Reck, M., Baumann, P., Klepetko, W., and Felip, E. (2010). Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), 116-119.
6. Ellis, R. P., and McGuire, T. G. (1993). Supply-side and demand-side cost sharing in health care. J. Econ. Perspect. 7, 135-151.
7. European Medicine Agency (EMA). (2012a). Summary of Product Characteristics. Gefitinib (Iressa). Available at: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001016/WC500036358.pdf [accessed September 4, 2012].
8. European Medicine Agency (EMA). (2012b). Summary of Product Characteristics. Erlotinib (Tarceva). Available at: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000618/WC500033994.pdf [accessed September 4, 2012].
9. Fiddelers, A. A., Dirksen, C. D., Dumoulin, J. C., van Montfoort, A. P., Land, J. A., Janssen, J. M., et al. (2009). Cost-effectiveness of seven IVF strategies: results of a Markov decision-analytic model. Hum. Reprod. 24, 1648-1655.
10. National Collaborating Centre for Women's and Children's Health. (2004). Fertility Assessment and Treatment for People with Fertility Problems. Clinical Guideline CG 11. Available at: http://www.nice.org.uk/CG011 [accessed September 4, 2012].
11. NCCN Practice Guidelines in Oncology. (2012a). National Comprehensive Cancer Network (NCCN). Asian Consensus Statement - Non-Small Cell Lung Cancer (Version 1.2009). Available at: http://www.nccn-asia.org/Adaptation.aspx?CatorID=3&KoID=4&Opsition=1001[accessed[accessed] September 4, 2012; last updated 2009, cited October 10, 2011].
12. NCCN Practice Guidelines in Oncology. (2012b). National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer (Version 2.2012). Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [accessed September 4, 2012; last updated 2011, cited October 10, 2011].
13. Neumann, P. J., and Johannesson, M. (1994). The willingness to pay for in vitro fertilization: a pilot study using contingent valuation. Med. Care 32, 686-699.
14. Nuijten, M. J., Mittendorf, T., and Persson, U. (2011). Practical issues in handling data input and uncertainty in a budget impact analysis. Eur. J. Health Econ. 12, 231-241.
15. Report of the Consumer Healthcare Products Association's Clinical/Medical Committee. (2010). White Paper on the Benefits of OTC Medicines in the United States. Pharmacy Today, October, 68-79.
16. Robson, S. J., Tan, W. S., Adeyemi, A., and Dear, K. B. G. (2009). Estimating the rate of cesarean section by maternal request: anonymous survey of obstetricians in Australia. Birth 36, 208-212.
17. st Century Nurse. Available at: http://www.21stcenturynurse.com/UKSalary.htm [accessed September 4, 2012].
18. Zweifel, P., Breyer, F., and Kifmann, M. (2009). Health Economics. Heidelberg: Springer Verlag.